10-K: Autolus Launches AUCATZYL, Expands CAR T-Cell Pipeline

Autolus Therapeutics reports its first commercial sales of AUCATZYL in the US, expands its CAR T-cell therapy pipeline for oncology and autoimmune diseases, and continues to incur significant losses.

Summary

• Autolus Therapeutics plc is an early commercial-stage biopharmaceutical company developing next-generation programmed T cell therapies for cancer and autoimmune diseases.
• The U.S. FDA approved AUCATZYL (obecabtagene autoleucel, also known as obe-cel) in November 2024 for adult patients (18 years and older) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL).
• Commercial launch and first sale of AUCATZYL in the United States occurred in January 2025, generating $74.3 million in net product revenue for the year ended December 31, 2025.
• The United Kingdom MHRA granted AUCATZYL conditional marketing authorization in April 2025, and NICE recommended its use in the NHS in November 2025, leading to a UK launch in January 2026.
• The European Commission granted marketing authorization for AUCATZYL in July 2025 for adult r/r B-ALL (age 26 and older), but the EU launch is currently on hold with no EU sales anticipated in 2026.
• Obe-cel is a B-lymphocyte antigen CD19 (CD19) chimeric antigen receptor (CAR) T cell therapy, manufactured at the company's Nucleus facility in Stevenage, U.K., which obtained MIA and GMP certificates in March 2024 and has a capacity for approximately 2,500 batches annually.
• Preliminary data from the Phase 1b CATULUS trial of obe-cel in pediatric r/r B-ALL and B-NHL, presented in December 2025, showed a 95.5% overall response rate (ORR) and 90.9% complete response (CR), with low rates of high-grade cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
• The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to obe-cel for pediatric r/r B-ALL in October 2025.
• Phase 1 CARLYSLE trial data for obe-cel in severe, refractory systemic lupus erythematosus (SLE), presented in December 2025, showed deep, durable responses and B-cell depletion with no ICANS or high-grade CRS.
• Obe-cel has advanced into a Phase 2 potentially pivotal LUMINA study for severe, refractory lupus nephritis (LN), which is now enrolling, and a Phase 1 dose escalation clinical trial for progressive multiple sclerosis (MS) initiated in October 2025.
• AUTO1/22, a dual-targeting CAR T, showed 83% MRD negative complete remissions in a Phase 1 pediatric ALL trial, with no antigen-negative relapse observed.
• AUTO8, a next-generation product candidate for multiple myeloma and AL amyloidosis, demonstrated 100% ORR in a Phase 1 multiple myeloma trial, with 7 CR/sCR and no Grade 3 ICANS or CRS.
• The first patient was dosed in the Phase 1 ALARIC trial for AUTO8 in light-chain amyloidosis in October 2025.
• A Phase 1 clinical trial of AUTO6NG in r/r neuroblastoma was initiated in December 2023 and is currently enrolling patients.
• The company reported a net loss of $287.5 million for the year ended December 31, 2025, compared to $220.7 million for 2024, with an accumulated deficit of $1,386.8 million.
• Net cash used in operating activities increased to $283.6 million in 2025 from $206.3 million in 2024.
• Strategic financing agreements include a final $30 million payment from Blackstone in December 2024 and a $250 million aggregate payment from BioNTech in February 2024, which included a $200 million equity investment and $50 million in upfront payments for licenses and revenue interest.
• The company paid $2.8 million in revenue share to Blackstone and $1.5 million to BioNTech in 2025.
• A $1.0 million clinical milestone payment was received from Moderna in 2025.
• Regulatory milestone payments of £10.0 million (FDA approval) and £6.0 million (EC approval) were paid to UCLB for AUCATZYL.
• The company had $104.1 million in cash and cash equivalents and $196.6 million in marketable securities as of December 31, 2025.
• Total full-time employees increased to 752 as of December 31, 2025, from 647 in 2024.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report. While the successful US and UK commercial launches of AUCATZYL and positive clinical data across the pipeline are strong operational achievements, the significant increase in net loss and cash burn, coupled with the delayed EU launch and loss of SME R&D tax benefits, indicate ongoing financial challenges and a continued reliance on future funding.

Positives

• FDA approval of AUCATZYL for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL) in November 2024.
• Successful commercial launch and first sales of AUCATZYL in the US in January 2025, generating $74.3 million in net product revenue in 2025.
• MHRA conditional marketing authorization for AUCATZYL in the UK in April 2025 and NICE recommendation for NHS use in England and Wales in November 2025, leading to a UK launch in January 2026.
• European Commission marketing authorization for AUCATZYL in July 2025 for adult r/r B-ALL.
• Positive preliminary data from Phase 1b CATULUS trial in pediatric r/r B-ALL and B-NHL, showing 95.5% overall response rate (ORR) and 90.9% complete response (CR), with low rates of high-grade cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
• FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to obe-cel for pediatric r/r B-ALL in October 2025.
• Positive data from Phase 1 CARLYSLE trial in severe refractory systemic lupus erythematosus (SLE), demonstrating deep, durable responses and B-cell depletion with no ICANS or high-grade CRS observed in 9 evaluable patients.
• Advancement of obe-cel into Phase 2 potentially pivotal LUMINA study for severe, refractory lupus nephritis (LN) with FDA alignment on trial design and potential registrational path.
• Initiation of Phase 1 BOBCAT trial for obe-cel in progressive multiple sclerosis (MS) in October 2025, expanding the autoimmune pipeline.
• Positive Phase 1 data for AUTO1/22 in pediatric ALL (CARPALL trial) showing 83% MRD negative CR and favorable tolerability, with no antigen-negative relapse.
• Positive Phase 1 data for AUTO8 in r/r multiple myeloma showing 100% ORR (7 CR/sCR) and no Grade 3 ICANS or CRS.
• First patient dosed in Phase 1 ALARIC trial for AUTO8 in light-chain amyloidosis in October 2025.
• The Nucleus manufacturing facility obtained Manufacturers Importation Authorization (MIA) and GMP certificate in March 2024, providing global supply capabilities.
• Real-world data from the ROCCA Consortium for AUCATZYL show improvements in both safety and efficacy compared to the FELIX clinical trial.
• Received a $1.0 million clinical milestone payment from Moderna in 2025.
• Blackstone Collaboration Agreement fully funded with the final $30 million payment received in December 2024.
• Significant strategic financing from BioNTech in February 2024, including a $200 million equity investment and $50 million in upfront payments.
• Obtained ISO 27001 certification for information security management systems in February 2025.

Negatives

• Reported a significant net loss of $287.5 million for the year ended December 31, 2025, a 30% increase from $220.7 million in 2024.
• Accumulated deficit reached $1,386.8 million as of December 31, 2025.
• Net cash used in operating activities increased to $283.6 million in 2025 from $206.3 million in 2024, indicating a higher cash burn.
• Interest income decreased by 41% to $19.0 million in 2025 from $32.4 million in 2024, primarily due to lower aggregate balances and yield of cash and marketable securities.
• Interest expense, net, surged by 295% to $36.7 million in 2025 from $9.3 million in 2024, mainly due to changes in valuation assumptions for collaboration liabilities.
• Recorded $12.3 million in inventory write-downs in 2025 due to excess, obsolescence, or shelf-life expiration.
• The EU launch of AUCATZYL is on hold, and no EU sales are anticipated in 2026, partly due to the voluntary withdrawal of obe-cel from the EU register of orphan medicinal products in June 2025, impacting potential revenue streams.
• The company no longer qualifies for the more beneficial SME R&D tax credit program from January 2025, which could reduce future tax benefits.
• The CMS policy to bill AUCATZYL's two infusions separately may delay revenue recognition for the company and treatment centers.

Risks

• The company is an early commercial-stage biopharmaceutical company and has incurred significant losses since its inception, expecting to continue incurring losses for the foreseeable future.
• AUCATZYL and any other product candidates, if approved, may fail to achieve the degree of market acceptance by physicians, patients, third-party payors, and others in the medical community necessary for commercial success.
• FDA investigation into secondary malignancies associated with CAR T cell therapies and other similar actions could result in increased government regulation, unfavorable public perception, stricter labeling requirements, and decreased demand.
• If the company is unable to fully develop its sales, marketing, and distribution capability on its own, or enter into sales, marketing, and distribution agreements with third parties, it may not be successful in commercializing AUCATZYL or other approved product candidates.
• The company's limited operating history may make it difficult to evaluate the success of its business to date and to assess its future viability.
• Additional funding will be needed to successfully commercialize AUCATZYL and complete the development of other product candidates, which may not be available on acceptable terms, if at all, potentially leading to substantial shareholder dilution.
• The company has incurred substantial obligations under license and collaboration agreements (e.g., Blackstone, BioNTech), which could impair its flexibility and access to other capital and adversely affect its financial position.
• If the company is unable to advance its product candidates through clinical development, obtain regulatory approval, and ultimately commercialize them, or experiences significant delays, its business will be materially harmed.
• The proprietary, next-generation T cell programming technologies, modular approach, and manufacturing platform represent emerging therapeutic approaches that face significant challenges and hurdles.
• Reliance on third-party collaborators for research, development, and commercialization of certain product candidates; collaborators may not perform as expected or may pursue competing products.
• Future success is highly dependent on regulatory approval of clinical-stage and preclinical programs, which require significant clinical or preclinical testing and face increasing post-approval regulatory burden and costs.
• Adverse side effects or other safety risks associated with product candidates (e.g., CRS, neurotoxicity, secondary T-cell malignancies) could delay or preclude approval, cause suspension/discontinuation of clinical trials, limit commercial profile, or result in significant negative consequences following marketing approval.
• The company may not be able to successfully create and scale its own manufacturing infrastructure for supply of programmed T cell product candidates for clinical trials and commercial sale.
• The manufacture of biologics, including the company's product candidates, is complex, and difficulties in production, process development, or scaling-out manufacturing capabilities could delay or stop supply.
• The company operates in a rapidly changing industry and faces significant competition, which may result in others discovering, developing, or commercializing products before or more successfully.
• If the company is unable to obtain and maintain patent protection for its T cell programming technologies and product candidates, or if the scope of protection is not sufficiently broad, competitors could develop and commercialize similar technologies.
• As an English public limited company, certain capital structure decisions will require shareholder approval, which may limit flexibility.
• General market conditions and macroeconomic trends, including those driven by geopolitical tension, supply chain disruptions, market volatility, inflation, fluctuations in foreign currency exchange rates, political changes, and changes in trade policies, could materially and adversely affect the business.
• Failure or perceived failure to comply with existing or future laws, regulations, contracts, self-regulatory schemes, standards, and other obligations related to data privacy and security (including security incidents) could harm the business.
• The company's current and potential future use of AI may not be successful and presents new risks and challenges, including cybersecurity risks, increased operating costs, and competitive disadvantages.
• Business disruptions, including those caused by ongoing geopolitical conflicts (e.g., war in Ukraine, Middle East conflicts), could seriously harm future revenue and financial condition and increase costs and expenses.
• The company is dependent on intellectual property obtained or licensed from third parties, and failure to comply with obligations could lead to loss of rights.
• Reliance on third parties to conduct preclinical and clinical trials; these third parties may not perform satisfactorily or meet deadlines.
• Cell-based therapies rely on the availability of reagents, specialized equipment, and other specialty materials, which may not be available on acceptable terms or at all, especially from sole or limited source vendors.
• Operating its own manufacturing facility requires significant resources, and a failure to successfully operate it could lead to substantial delays.
• The incidence and prevalence for target patient populations for AUCATZYL and other product candidates have not been established with precision, and market opportunities may be smaller than estimated.
• The company may expend resources to pursue a particular product candidate or indication and fail to capitalize on more profitable opportunities.
• Breakthrough therapy designation (FDA) or PRIME designation (EMA) may not be obtained, or accelerated approval may prolong the regulatory process.
• As a company based outside the United States, the business is subject to economic, political, regulatory, and other risks associated with international operations, including tariffs and exchange rate fluctuations.
• The trading price of the company's ADSs has been and may continue to be highly volatile.
• Future sales of ADSs in the public market could cause the share price to decline.
• Senior management, directors, and principal shareholders have the ability to control or significantly influence all matters submitted to shareholders for approval.
• The rights of shareholders may differ from the rights typically offered to shareholders of a U.S. corporation.
• Holders of ADSs may not have the same voting rights as holders of ordinary shares and may not receive voting materials in time.
• No anticipated cash dividends; capital appreciation, if any, will be ADS holders' sole source of gains.
• There could be adverse U.S. federal income tax consequences to U.S. Holders if the company is classified as a Passive Foreign Investment Company (PFIC).
• Future changes to tax laws could materially adversely affect the company and reduce net returns to shareholders.
• Tax authorities may disagree with tax positions, resulting in unanticipated costs, taxes, or non-realization of expected benefits.
• The company may be unable to use net operating loss and tax credit carryforwards and certain built-in losses to reduce future tax payments or benefits from favorable U.K. tax legislation (e.g., no longer qualifies for SME R&D tax credit).
• Significant costs and demands upon management as a result of being a public company, with increased compliance initiatives.
• The company may lose its foreign private issuer status in the future, or reporting exemptions for foreign private issuers may be reduced, resulting in significant additional costs and expenses.
• Provisions in the U.K. City Code on Takeovers and Mergers that may have anti-takeover effects do not currently apply to the company.
• Shareholders may face difficulties in protecting their interests, and their ability to protect rights through U.S. federal courts may be limited due to the company's incorporation in England and Wales and international operations.
• As an English public limited company, certain capital structure decisions will require shareholder approval, limiting flexibility.
• If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about the company, its business, or its market, the price and trading volume of ADSs could decline.
• Changes to promotion and advertising rules and regulations may potentially adversely impact sales of products.

Future Outlook

Autolus Therapeutics expects to continue incurring significant expenses and increasing operating losses for the foreseeable future as it expands commercialization of AUCATZYL, makes required payments under collaboration agreements, maintains manufacturing capacity, and advances its pipeline. The company does not anticipate any EU sales of AUCATZYL in 2026 and expects the Phase 2 CATULUS trial to be fully enrolled in the first half of 2027, with initial data from the BOBCAT (MS) and ALARIC (AL amyloidosis) trials, and the CARPALL Phase 1 extension, expected by the end of 2026. The company plans to launch approved products first in the US, then UK, EU, and other major markets, and anticipates leasing additional space while benefiting from a lower long-term corporation tax rate in the UK due to R&D and Patent Box regimes, though future healthcare reforms and the EU Pharma Package could impact pricing and market exclusivity.

Management Comments

• "We believe our programmed T cell therapies have the potential to be best-in-class and offer patients substantial benefits over the existing standard of care, including the potential for cure in some patients."
• "We intend for the Nucleus to meet the global supply demands of AUCATZYL."
• "We believe our leadership in T cell programming technologies will provide us with a competitive advantage as we look to develop future generations of T cell therapies targeting both hematological cancers, solid tumors and autoimmune diseases, including potential products that could have a sufficient tolerability profile to enable use in outpatient settings."
• "We believe that this autologous approach has the potential to be both the safest and most therapeutically effective approach to manufacturing CAR T cells."
• "We believe our commercial product and our clinical-stage product candidates and our approach to T cell programming have the potential to address these limitations [of current therapies]."
• "We believe obe-cel's potential advantages over other autoimmune therapies that are approved or in development include its differentiated mechanism of action via its fast-off rate CD19 binder, the existing clinical data and approval in r/r B-ALL and our established manufacturing and commercial capabilities."
• "We expect that data supporting the safety and manufacture of obe-cel in r/r B-ALL could potentially be useful to support the development of obe-cel in autoimmune indications."
• "Our established commercial systems and manufacturing infrastructure for AUCATZYL/obe-cel could be leveraged to support an autoimmune indication."
• "We believe that the design of AUTO8 has the potential to induce deep and durable responses and extend the durability of effect over other approved BCMA CARs and those currently in development."
• "We believe our scalable closed-system manufacturing process, along with our proprietary and modular T cell programming technologies, would be challenging and costly for potential competitors to replicate."
• "Management considers that there are no conditions or events, in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least one year from the date the consolidated financial statements are issued."

Industry Context

StockSavvy.ai notes that Autolus is operating in the highly competitive and rapidly evolving CAR T-cell therapy space, which has seen significant advancements from major players like Novartis, Gilead, and BMS. The company's focus on a differentiated safety profile for AUCATZYL (obe-cel) with its fast off-rate CD19 binder is a strategic move to carve out market share against established competitors like Tecartus and Kymriah, especially in adult r/r B-ALL where Tecartus is a direct competitor. The expansion into autoimmune diseases (SLE, LN, MS) with obe-cel positions Autolus in an emerging and promising area for CAR T therapies, where initial academic trials have shown profound improvements. This diversification could mitigate risks associated with oncology-only pipelines and tap into a significant unmet medical need. The development of dual-targeting CAR T candidates like AUTO1/22 and AUTO8 directly addresses known limitations of current CAR T therapies, such as antigen loss and persistence, which are critical challenges in achieving durable responses in both hematological and solid tumors. The industry is also seeing the emergence of allogeneic (off-the-shelf) CAR T-cell therapies and in vivo CAR T-cell therapy, which could offer convenience advantages over autologous products. Autolus acknowledges this competition but highlights the current limitations of allogeneic products in terms of durable activity, suggesting a continued competitive edge for autologous therapies like its own. The increasing regulatory scrutiny on pharmaceutical pricing and advertising, as well as evolving data privacy laws, reflects broader industry trends that all biopharmaceutical companies must navigate.

Comparison to Industry Standards

• AUCATZYL (obe-cel) is approved for adult r/r B-ALL, competing directly with Tecartus (Kite/Gilead) and Kymriah (Novartis, approved for patients up to 25 years). Autolus believes AUCATZYL has a differentiated safety profile and potential for longer-term outcomes compared to these approved therapies.
• Real-world data from the ROCCA Consortium for AUCATZYL show improvements in both safety and efficacy compared to the FELIX clinical trial, suggesting strong performance in a commercial setting, potentially surpassing initial trial results.
• Obe-cel's fast off-rate binder is designed to minimize excessive T-cell activation, potentially leading to reduced Cytokine Release Syndrome (CRS) and increased T-cell engraftment compared to high-affinity binders used by other CAR T therapies, which have shown severe and life-threatening toxicities.
• In pediatric B-ALL, Phase 1b CATULUS trial data for obe-cel showed 95.5% ORR and 90.9% CR, with low rates of high-grade CRS and ICANS. This compares favorably to Kymriah, which has shown approximately 80% complete molecular response but with ~40% relapse at six months, often due to CD19 negative disease.
• For autoimmune diseases, the Phase 1 CARLYSLE trial in SLE showed deep, durable responses and B-cell depletion with no ICANS or high-grade CRS. This favorable safety profile in a cancer setting has the potential to drive acceptability in rheumatology, where existing B-cell depleting agents like rituximab (anti-CD20) and belimumab (anti-BAFF) have shown limited efficacy and can have serious side effects.
• Obe-cel is the only autologous CD19 CAR T-cell therapy being developed for lupus with an approval in another indication, potentially leveraging existing safety and manufacturing data to accelerate development in autoimmune indications.
• In progressive MS, CD19-targeting CAR T cells like obe-cel can penetrate the CNS compartment, unlike anti-CD20 monoclonal antibodies (e.g., ocrelizumab), which have limited access to autoreactive B cells within the CNS. Ocrelizumab, for example, showed a modest 6% absolute reduction in confirmed disability progression for PPMS.
• AUTO1/22, a dual-targeting CAR T, is designed to reduce antigen-negative relapse, a common cause of treatment failure in CAR T-cell therapy (e.g., observed in Kymriah for pediatric B-ALL). Phase 1 data showed no relapse due to antigen-negative escape.
• AUTO8, a dual-targeting CAR T for multiple myeloma, is designed to induce deep and durable responses and extend durability over other approved BCMA CARs (e.g., Abecma, Carvykti) and those in development, which primarily target BCMA alone. AUTO8's dual-targeting of BCMA and CD19 aims to improve efficacy against low BCMA expression and reduce antigen escape.

Management Changes

Corporate Governance

Legal Proceedings

• The company was not a party to any litigation and did not have contingency reserves established for any liabilities as of December 31, 2025 and 2024.

Related Party Transactions

• **BioNTech SE**: Entered into a License and Option Agreement in February 2024, receiving a $10.0 million initial payment for licenses and options, and a $40.0 million upfront payment for an obe-cel product revenue interest. The company issued and sold 33.3 million ADSs to BioNTech for $200.0 million in a private placement in February 2024. Paid $1.5 million in revenue share payments to BioNTech in 2025. BioNTech has the right to appoint a non-executive director and purchase equity in future financings to maintain ownership thresholds. BioNTech's option to co-fund AUTO1/22 and AUTO6NG expired unexercised for AUTO1/22 in February 2025, and its option to negotiate a joint Manufacturing and Commercial Services Agreement (MCSA) expired unexercised in August 2025. The carrying amount of the BioNTech Liability was $43.5 million as of December 31, 2025.
• **Blackstone (BXLS V Autobahn L.P.)**: Received the final $30.0 million Blackstone Development Payment in December 2024, completing the $150 million funding under the Strategic Collaboration and Financing Agreement. Paid $2.8 million in revenue share payments to Blackstone in 2025. Issued a warrant to Blackstone to purchase up to 3,265,306 ADSs at an exercise price of $7.35 per ADS, exercisable until November 6, 2026. William Young, Ph.D., was appointed to the board as Blackstone's designee. The carrying amount of the Blackstone Collaboration Agreement liability was $236.7 million as of December 31, 2025.
• **Fidelity Management & Research Company, LLC**: Purchased 5,808,333 ADSs for $34.9 million in the February 2024 underwritten offering, as a holder of more than 5% of the company's share capital in 2024.
• **Deep Track Capital, LP**: Purchased 3,750,000 ADSs for $30.0 million in the February 2024 underwritten offering, as a holder of more than 5% of the company's share capital in 2024.
• **UCL Business Ltd. (UCLB)**: Paid regulatory milestone payments of £10.0 million (FDA approval in November 2024) and £6.0 million (EC approval in July 2025) for AUCATZYL. Less than $0.1 million was payable to UCLB in 2025 relating to income allocable to sublicensed intellectual property rights.
• **ModernaTX, Inc.**: Received a $1.0 million clinical milestone payment in 2025 related to a proprietary binder licensed in 2022.
• **Senior Management and Directors**: Compensation arrangements, including equity awards, are detailed in Item 11. Deeds of indemnity have been entered into with each director and member of senior management.

Stakeholder Impact

• **Shareholders**: Face potential for substantial dilution from future capital raises, market price volatility of ADSs, and differences in voting rights compared to U.S. corporations. No anticipated cash dividends mean capital appreciation is the sole source of gains. Concentration of ownership by major shareholders could influence corporate decisions. Exclusive forum provisions may limit legal recourse.
• **Patients**: Benefit from increased access to AUCATZYL in the US and UK for r/r B-ALL, and potential new therapies for pediatric B-ALL, B-NHL, SLE, LN, and MS. However, they face inherent risks of adverse side effects from CAR T therapies and potential delays in access due to regulatory or manufacturing issues.
• **Employees**: Experience growth in headcount and operations, but also intense competition for qualified personnel in cell therapy. Equity incentive plans are in place for motivation and retention. There is a risk of misconduct or non-compliance.
• **Healthcare Providers/Treatment Centers**: Need to establish specialized infrastructure and undergo training for administering CAR T therapies. Reimbursement policies, such as the CMS split billing for AUCATZYL, can impact their revenue recognition and operational processes.
• **Third-Party Payors**: Their coverage and reimbursement decisions are critical for product acceptance and sales. They are under increasing pressure to implement pricing and cost-containment measures, which could affect the company's profitability.
• **Suppliers/Partners**: The company's reliance on limited vendors for critical materials creates supply chain risks. Collaboration agreements with Blackstone, BioNTech, Moderna, and UCLB involve complex financial obligations and shared risks and benefits.
• **Regulatory Authorities**: Maintain ongoing scrutiny and extensive regulation of biopharmaceutical products, with potential for investigations, sanctions, or withdrawal of approvals if compliance is not met.

Next Steps

• Optimize manufacturing operations to improve gross margin and innovate on a next-generation manufacturing platform.
• Evaluate potential pricing and feasibility of market entry opportunities in certain EU countries for AUCATZYL.
• Develop obe-cel for additional indications, including pediatric r/r B-ALL, lupus nephritis (LN), and progressive multiple sclerosis (MS).
• Fully enroll the Phase 2 cohort of the CATULUS trial (pediatric r/r B-ALL) in the first half of 2027.
• Report initial data from the Phase 1 BOBCAT trial (MS) at the end of 2026.
• Report initial data from the Phase 1 ALARIC trial (AL amyloidosis) at the end of 2026.
• UCL collaborators expect to report first data from the CARPALL Phase 1 extension in late 2026.
• Continue to evaluate other possible solid tumor indications.
• Expand global commercialization capabilities over time, focusing on early presence in the US, UK, and parts of Europe.
• Potentially pursue strategic collaborations with third parties to maximize commercial potential of product candidates.
• Advance preclinical programs to clinical trials.
• Continue to identify, recruit, retain, incentivize, and integrate employees.
• Continue to strengthen internal controls over financial reporting.
• Assess Asset Retirement Obligation (ARO) as more related assets are brought into use at The Nucleus facility.
• Comply with the Master Service Agreement with AGC Biologics S.p.A. for lentiviral vector supply, including minimum purchase commitments.

Key Dates

Recommendation

Autolus Therapeutics has made significant progress with the commercial launch of AUCATZYL in the US and UK, and positive clinical data from its pipeline in autoimmune diseases and other oncology indications are encouraging. The strategic collaborations with BioNTech and Blackstone provide substantial funding and validation. However, the company continues to incur significant net losses and cash burn, and the delayed EU launch for AUCATZYL due to pricing challenges highlights commercial hurdles. The loss of SME R&D tax benefits and increased interest expenses also weigh on profitability. While the long-term potential of its CAR T-cell platform is strong, the current financial performance and ongoing need for capital suggest a "hold" recommendation, as investors should monitor the company's ability to achieve profitability, expand market access, and manage its cash flow effectively.

Keywords

CAR T-cell therapy, Oncology, Autoimmune diseases, B-ALL, Lupus Nephritis, Multiple Sclerosis, Biopharmaceutical, Gene therapy, Clinical trials, Regulatory approval, AUCATZYL, Obe-cel, AUTO1/22, AUTO8, AUTO6NG, Manufacturing, Biotechnology, SEC filing, Financial results, Risk management, Intellectual property, Strategic collaborations, Blackstone, BioNTech, Moderna, FDA, MHRA, EMA, NICE, Immunotherapy